GAAP SG&A expenditures had been $65.9 million for Q1 2011, in comparison to $50.6 million for Q1 2010. Balance Sheet: By March 31, 2011, the business acquired $348.8 million in cash, cash equivalents and marketable securities, compared to $361.6 million at the final end of 2010. The amount outstanding by the end of the quarter reflected outflows of approximately $114 million linked to the Taligen Therapeutics and Orphatec Pharmaceuticals acquisitions and inflows of $60 million in short-term borrowing through the first one fourth. ‘In the early weeks of 2011, we achieved steady development in serving sufferers with PNH in our core territories, and started laying the original groundwork for growing into fresh major countries.68 % of investigators said this was a ‘very important’ element in their participation compared to just 26 % of EUROPEAN physicians. There are numerous of potential factors because of this difference. U.S. Investigators likely encounter higher operating costs to manage their research activities. For instance, 88 % of U.S. Investigators reported having at least one research coordinator on staff, which is known as an expense of the study facility, as compared to 51 % in Western Europe. U.S. Investigators also show higher degrees of concern over issues such as insurance and liability coverage for participants, that could also be factors contributing to an increased cost structure to carry out research.